NZYM B Novozymes A/S Class B

Trading by management and close relations of management

Trading by management and close relations of management

Please read the announcement in PDF

Attachment



EN
22/08/2025

Underlying

NZYM BNovozymes A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novozymes A/S Class B

 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Trading by management and close relations of management

Trading by management and close relations of management Please read the announcement in PDF Attachment

4h / 51m 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Trading by management and close relations of management

Trading by management and close relations of management Please read the announcement in PDF Attachment

9h / 1m 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Novonesis delivered 9% organic sales growth in H1 and full-year outloo...

Novonesis delivered 9% organic sales growth in H1 and full-year outlook range narrowed to 6-8% COPENHAGEN, Denmark – August 21, 2025. Novonesis delivered 9% organic sales growth in H1 and full-year outlook range narrowed to 6-8%. Ester Baiget, President & CEO: “I’m very pleased with 9% organic sales growth in the first half of the year. Demand for our biosolutions is strong, and consequently, we are lifting the lower end of our full-year guidance to 6-8% organic sales growth. Our profitability also remains solid, despite strong headwinds from currencies. With a strong foundation in place, ...

August 21, 2025 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Interim report H1 2025

Interim report H1 2025 9% organic sales growth in H1 and FY outlook range narrowed to 6-8% Ester Baiget, President & CEO: “I’m very pleased with 9% organic sales growth in the first half of the year. Demand for our biosolutions is strong, and consequently, we are lifting the lower end of our full-year guidance to 6-8% organic sales growth.  Our profitability also remains solid, despite strong headwinds from currencies. With a robust foundation in place, we are well positioned to accelerate into our next strategy period until 2030, where we will continue to significantly invest in what mak...

August 21, 2025 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

2030 financial targets announced: Organic sales growth acceleration, m...

2030 financial targets announced: Organic sales growth acceleration, margin expansion and ROIC improvement COPENHAGEN, Denmark - August 20, 2025. Novonesis today announces its ‘GROW’ strategy and long-term targets for the strategy period until 2030 focusing on an acceleration of the core business and significant re-investments to secure long-term growth. By 2030, the company expects to deliver an organic sales CAGR of 6-9%, an adjusted EBITDA margin of ~39% and an adjusted ROIC excl. goodwill of ~16%. Novonesis is well positioned to continue to drive strong performance in biosolutions. The...

August 20, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch